Danish medico giant Novo Nordisk, a world leader in diabetes care, has inaugurated its USD 100 m expanded facility in Clayton, North Carolina, and plans to construct a new factory in China, investments totalling more than DKK 2 bn (USD 360 m). Per Valstorp, head of Novo Nordisk facilities says: "We are doing well on the US market, and now it is big enough for us to start producing FlexPens [disposable insulin pens – Ed] instead of transporting them from Denmark".
The expansion at the Clayton facility has created 50 new jobs, resulting in a total workforce of 400. Mike DeSherbinin, director of the Johnston County Economic Development Office, comments: "By cultivating and maintaining an educated workforce and creating exciting jobs in pharmaceutical manufacturing, Novo Nordisk is providing access to some of the best paid and rewarding jobs in the area."
Novo Nordisk also plans to expand on the Chinese market. Jesper Brandgaard, finance director of Novo Nordisk says: "In the next year or two we will start to plan a factory which will make insulin cartridges. The aim is both to gain low wage costs and reduce the impact of Chinese currency fluctuations." Novo Nordisk forecasts its revenues on the Chinese market will pass the DKK 2 bn (USD 360 m) mark this year.
Headquartered in Denmark, Novo Nordisk employs more than 23,600 people in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. The news was reported by national daily newspaper Jyllands-Posten and on the Novo Nordisk website.